California State Teachers Retirement System Acquires 3,409 Shares of Glaukos Co. (NYSE:GKOS)

California State Teachers Retirement System lifted its position in Glaukos Co. (NYSE:GKOS - Free Report) by 7.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 50,949 shares of the medical instruments supplier's stock after purchasing an additional 3,409 shares during the period. California State Teachers Retirement System owned 0.09% of Glaukos worth $7,639,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. IFP Advisors Inc acquired a new position in shares of Glaukos during the fourth quarter valued at approximately $43,000. Asset Planning Inc purchased a new stake in shares of Glaukos in the 4th quarter valued at approximately $90,000. CoreCap Advisors LLC lifted its position in shares of Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after buying an additional 200 shares during the last quarter. Picton Mahoney Asset Management purchased a new position in shares of Glaukos during the fourth quarter worth approximately $125,000. Finally, SBI Securities Co. Ltd. purchased a new position in Glaukos in the 4th quarter valued at $153,000. Hedge funds and other institutional investors own 99.04% of the company's stock.

Insider Activity

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. This represents a 2.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of analyst reports. Stifel Nicolaus cut their price objective on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Morgan Stanley decreased their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Wells Fargo & Company lowered shares of Glaukos from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $160.00 to $86.00 in a report on Thursday, May 1st. Truist Financial reaffirmed a "buy" rating and set a $135.00 price target (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Finally, Mizuho cut their target price on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and a consensus target price of $134.67.

Glaukos Trading Down 3.7%

GKOS traded down $3.50 during trading on Wednesday, reaching $90.99. 907,302 shares of the company's stock were exchanged, compared to its average volume of 710,233. The company's fifty day moving average price is $92.04 and its 200-day moving average price is $122.19. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a market capitalization of $5.20 billion, a PE ratio of -31.70 and a beta of 0.83. Glaukos Co. has a fifty-two week low of $77.10 and a fifty-two week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The business had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm's revenue was up 24.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.70) earnings per share. As a group, equities analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.